Cancer Biotherapy and Radiopharmaceuticals : Impact Factor & More
eISSN: 1557-8852pISSN: 1084-9785
Share this on:
Key Metrics
CiteScore 
5.2
H-Index
66
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.71
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cancer Biotherapy and Radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | MARY ANN LIEBERT, INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1996 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Biotherapy and Radiopharmaceuticals ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Biotherapy and Radiopharmaceuticals
Characterization of Adverse Drug Effects to Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
On the Importance of Extracting the Needle from the Haystack.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
Precision Oncology with 177Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer.
- 6 May 2026
- Cancer biotherapy & radiopharmaceuticals
Expanding the Therapeutic Window in Oncology: Modern Strategies and Future Directions.
- 6 May 2026
- Cancer biotherapy & radiopharmaceuticals
Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients.
- 4 May 2026
- Cancer biotherapy & radiopharmaceuticals
Characterization of Adverse Drug Effects to Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
On the Importance of Extracting the Needle from the Haystack.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma.
- 7 May 2026
- Cancer biotherapy & radiopharmaceuticals
Precision Oncology with 177Lu-PSMA-617 Radionuclide Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer.
- 6 May 2026
- Cancer biotherapy & radiopharmaceuticals
Expanding the Therapeutic Window in Oncology: Modern Strategies and Future Directions.
- 6 May 2026
- Cancer biotherapy & radiopharmaceuticals
Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients.
- 4 May 2026
- Cancer biotherapy & radiopharmaceuticals
FAQs on Cancer Biotherapy and Radiopharmaceuticals
How long has Cancer Biotherapy and Radiopharmaceuticals been actively publishing? 
What is the publishing frequency of Cancer Biotherapy and Radiopharmaceuticals?
How many articles did Cancer Biotherapy and Radiopharmaceuticals publish last year?
What is the eISSN & pISSN for Cancer Biotherapy and Radiopharmaceuticals?
What is Citescore for Cancer Biotherapy and Radiopharmaceuticals?
What is the H Index for Cancer Biotherapy and Radiopharmaceuticals ?
What is SNIP score for Cancer Biotherapy and Radiopharmaceuticals?
What is the SJR for Cancer Biotherapy and Radiopharmaceuticals?
Who is the publisher of Cancer Biotherapy and Radiopharmaceuticals?
